These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23693152)

  • 1. UNC1062, a new and potent Mer inhibitor.
    Liu J; Zhang W; Stashko MA; Deryckere D; Cummings CT; Hunter D; Yang C; Jayakody CN; Cheng N; Simpson C; Norris-Drouin J; Sather S; Kireev D; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
    Eur J Med Chem; 2013 Jul; 65():83-93. PubMed ID: 23693152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
    Inoue S; Yamane Y; Tsukamoto S; Murai N; Azuma H; Nagao S; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
    Bioorg Med Chem Lett; 2021 Sep; 48():128247. PubMed ID: 34271070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.
    Zhang W; DeRyckere D; Hunter D; Liu J; Stashko MA; Minson KA; Cummings CT; Lee M; Glaros TG; Newton DL; Sather S; Zhang D; Kireev D; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
    J Med Chem; 2014 Aug; 57(16):7031-41. PubMed ID: 25068800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.
    Zhang W; Zhang D; Stashko MA; DeRyckere D; Hunter D; Kireev D; Miley MJ; Cummings C; Lee M; Norris-Drouin J; Stewart WM; Sather S; Zhou Y; Kirkpatrick G; Machius M; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
    J Med Chem; 2013 Dec; 56(23):9683-92. PubMed ID: 24195762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.
    Baladi T; Aziz J; Dufour F; Abet V; Stoven V; Radvanyi F; Poyer F; Wu TD; Guerquin-Kern JL; Bernard-Pierrot I; Garrido SM; Piguel S
    Bioorg Med Chem; 2018 Nov; 26(20):5510-5530. PubMed ID: 30309671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.
    Zhang W; McIver AL; Stashko MA; DeRyckere D; Branchford BR; Hunter D; Kireev D; Miley MJ; Norris-Drouin J; Stewart WM; Lee M; Sather S; Zhou Y; Di Paola JA; Machius M; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
    J Med Chem; 2013 Dec; 56(23):9693-700. PubMed ID: 24219778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of MERTK Inhibitors UNC569 and UNC1062 on the Growth of Acute Myeloid Leukaemia Cells.
    Koda Y; Itoh M; Tohda S
    Anticancer Res; 2018 Jan; 38(1):199-204. PubMed ID: 29277773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.
    Christoph S; Deryckere D; Schlegel J; Frazer JK; Batchelor LA; Trakhimets AY; Sather S; Hunter DM; Cummings CT; Liu J; Yang C; Kireev D; Simpson C; Norris-Drouin J; Hull-Ryde EA; Janzen WP; Johnson GL; Wang X; Frye SV; Earp HS; Graham DK
    Mol Cancer Ther; 2013 Nov; 12(11):2367-77. PubMed ID: 23997116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors.
    Szabadkai I; Torka R; Garamvölgyi R; Baska F; Gyulavári P; Boros S; Illyés E; Choidas A; Ullrich A; Őrfi L
    J Med Chem; 2018 Jul; 61(14):6277-6292. PubMed ID: 29928803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment.
    Li MC; Lai YL; Kuo PH; Reddy JS; Chen CM; Manimala J; Wang PC; Wu MS; Chang CY; Yang CM; Lin CY; Huang YC; Chiu CH; Chang L; Lin WH; Yeh TK; Yen WC; Hsieh HP
    J Med Chem; 2024 Jul; 67(13):10906-10927. PubMed ID: 38913493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a potent and selective Axl inhibitor in preclinical model.
    Inoue S; Yamane Y; Tsukamoto S; Azuma H; Nagao S; Murai N; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
    Bioorg Med Chem; 2021 Jun; 39():116137. PubMed ID: 33930844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.
    Ng PS; Foo K; Sim S; Wang G; Huang C; Tan LH; Poulsen A; Liu B; Tee DHY; Ahmad NHB; Wang S; Ke Z; Lee MA; Kwek ZP; Joy J; Anantharajan J; Baburajendran N; Pendharkar V; Manoharan V; Vuddagiri S; Sangthongpitag K; Hill J; Keller TH; Hung AW
    Bioorg Med Chem; 2021 Nov; 49():116437. PubMed ID: 34600239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for selective small molecule kinase inhibition of activated c-Met.
    Rickert KW; Patel SB; Allison TJ; Byrne NJ; Darke PL; Ford RE; Guerin DJ; Hall DL; Kornienko M; Lu J; Munshi SK; Reid JC; Shipman JM; Stanton EF; Wilson KJ; Young JR; Soisson SM; Lumb KJ
    J Biol Chem; 2011 Apr; 286(13):11218-25. PubMed ID: 21247903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate.
    Keung W; Boloor A; Brown J; Kiryanov A; Gangloff A; Lawson JD; Skene R; Hoffman I; Atienza J; Kahana J; De Jong R; Farrell P; Balakrishna D; Halkowycz P
    Bioorg Med Chem Lett; 2017 Feb; 27(4):1099-1104. PubMed ID: 28082036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
    Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
    Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.
    Lee-Sherick AB; Eisenman KM; Sather S; McGranahan A; Armistead PM; McGary CS; Hunsucker SA; Schlegel J; Martinson H; Cannon C; Keating AK; Earp HS; Liang X; DeRyckere D; Graham DK
    Oncogene; 2013 Nov; 32(46):5359-68. PubMed ID: 23474756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research Progress of Axl Inhibitors.
    Sun ZG; Liu JH; Zhang JM; Qian Y
    Curr Top Med Chem; 2019; 19(15):1338-1349. PubMed ID: 31218961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationship of 7-aryl-2-anilino-pyrrolopyrimidines as Mer and Axl tyrosine kinase inhibitors.
    Chung SH; Park J; Lee JW; Song J; Jung D; Min KH
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1822-1833. PubMed ID: 32972253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
    Cummings CT; Zhang W; Davies KD; Kirkpatrick GD; Zhang D; DeRyckere D; Wang X; Frye SV; Earp HS; Graham DK
    Mol Cancer Ther; 2015 Sep; 14(9):2014-22. PubMed ID: 26162689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient Arylation of 2,7-Naphthyridin-1(2
    Wang MS; Xu HC; Gong Y; Qu RY; Zhuo LS; Huang W
    ACS Comb Sci; 2020 Sep; 22(9):457-467. PubMed ID: 32589005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.